Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

被引：5
|
作者：
Bowlus, C. [1 ]
Pockros, P. [2 ]
Kremer, A. E. [3 ]
Pares, A. [4 ]
Forman, L. [5 ]
Drenth, J. P. [6 ]
Ryder, S. [7 ,8 ]
Malecha, E. S. [9 ]
Pencek, R. [9 ]
Iloeje, U. [9 ]
Macconell, L. [9 ]
Shapiro, D. [9 ]
Pierre, B. [10 ]
机构：
[1] Univ Calif Davis, Sacramento, CA 95817 USA
[2] Scripps Clin, La Jolla, CA USA
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[4] Univ Barcelona, Hosp Clin, IDIBAPS, CIBERehd, Barcelona, Spain
[5] Univ Colorado Denver, Sch Med, Aurora, CO USA
[6] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[7] Nottingham Univ Hosp NHS Trust, Natl Inst Hlth Res, NDDBRU, Nottingham, England
[8] Univ Nottingham, Nottingham, England
[9] Intercept Pharmaceut Inc, San Diego, CA USA
[10] Serv Anat Pathol, Clichy, France
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30441-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LBP-014
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [11] LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, G.
    Kowdley, K.
    Mason, A.
    Luketic, V.
    Gordon, S.
    Vincent, C.
    Mayo, M.
    Pares, A.
    Chapman, R.
    Lindor, K.
    Esguerra, M.
    Eliot, L.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S372 - S372
  • [12] LONG-TERM EFFECTS OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS ON INFLAMMATORY MARKERS
    Hirschfield, Gideon M.
    Nevens, Frederik
    Shiffman, Mitchell L.
    Drenth, Joost P. H.
    Bowlus, Christopher L.
    Vargas, Victor
    Andreone, Pietro
    Ryder, Stephen
    Liberman, Alexander
    Malecha, Elizabeth Smoot
    MacConell, Leigh
    Trauner, Michael
    GUT, 2019, 68 : A115 - A116
  • [13] Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
    Pares, Albert
    Shiffman, Mitchell
    Vargas, Victor
    Invernizzi, Pietro
    Malecha, Elizabeth S.
    Liberman, Alexander
    MacConell, Leigh
    Hirschfield, Gideon
    LIVER INTERNATIONAL, 2020, 40 (05) : 1121 - 1129
  • [14] A LONG TERM SAFETY EXTENSION TRIAL OF THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) AND UDCA IN PRIMARY BILIARY CIRRHOSIS (PBC)
    Hirschfield, Gideon M.
    Mason, Andrew L.
    Gordon, Stuart C.
    Luketic, Velimir A.
    Mayo, Marlyn
    Vincent, Catherine
    Lindor, Keith D.
    Pares, Albert
    Kowdley, Kris V.
    Trauner, Michael
    Esguerra, Maria
    Boehm, Olaf
    Shapiro, David A.
    HEPATOLOGY, 2011, 54 : 429A - 429A
  • [15] TREATMENT WITH SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND PRIOR EXPERIENCE WITH OBETICHOLIC ACID OR FIBRATES
    Gulamhusein, Aliya
    Neff, Guy
    Goel, Aparna
    Mayo, Marlyn J.
    Stanca, Carmen M.
    Bowlus, Christopher L.
    Forman, Lisa
    Invernizzi, Pietro
    Nevens, Frederik
    Zigmond, Ehud
    Zuckerman, Eli
    Yang, Ke
    Choi, Yun-Jung
    Steinberg, Alexandra
    Mcwherter, Charles A.
    Kowdley, Kris V.
    GASTROENTEROLOGY, 2022, 162 (07) : S1192 - S1193
  • [16] Long-term prospective follow-up of a primary biliary cholangitis (PBC) multicenter cohort treated with Obeticholic Acid (OCA). Interaction effect of triple therapy with fibrates
    Gomez-Dominguez, Elena
    Molina, Esther
    Garcia-Buey, Luisa
    Casado, Marta
    Berenguer, Marina
    Conde, Isabel
    Angel Simon, Miguel
    Costa-Moreira, Pedro
    Macedo, Guilherme
    Morillas, Rosa M.
    Presa, Jose
    Jorquera, Francisco
    Ampuero, Javier
    Sousa-Martin, Jose Manuel
    Olveira Martin, Antonio
    Hernandez Guerra, Manuel
    Ignacio Arenas, Juan
    Santos, Arsenio
    Carvalho, Armando
    Uriz Otano, Juan Isidro
    Gutierrez Garcia, Maria Luisa
    Perez-Fernandez, Elia
    Fernandez-Rodriguez, Conrado
    JOURNAL OF HEPATOLOGY, 2023, 78 : S366 - S367
  • [17] Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis
    Bowlus, Christopher L.
    Pockros, Paul J.
    Kremer, Andreas E.
    Pares, Albert
    Forman, Lisa M.
    Drenth, Joost P. H.
    Ryder, Stephen D.
    Terracciano, Luigi
    Jin, Yuying
    Liberman, Alexander
    Pencek, Richard
    Iloeje, Uche
    MacConell, Leigh
    Bedossa, Pierre
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (05) : 1170 - +
  • [18] EFFICACY OF OBETICHOLIC ACID (OCA) VS PLACEBO AND EXTERNAL CONTROL (EC) ON CLINICAL OUTCOMES IN PRIMARY BILIARY CHOLANGITIS (PBC)
    Kowdley, Kris V.
    Brookhart, M. Alan
    Hirschfield, Gideon
    Coombs, Charles
    Malecha, Elizabeth
    Mayne, Tracy
    Ness, Erik
    Li, Jing
    Breskin, Alexander
    Rathnayaka, Nuvan
    Mells, George
    Jones, David
    Trivedi, Palak J.
    Hansen, Bettina E.
    Smith, Rachel
    Wason, James
    Hiu, Shaun
    Kareithi, Dorcas N.
    Mason, Andrew L.
    Bowlus, Christopher L.
    Muller, Kate
    Carbone, Marco
    Berenguer, Marina
    Milkiewicz, Piotr
    Adekunle, Femi
    Villamil, Alejandra
    HEPATOLOGY, 2023, 77 (05) : E144 - E146
  • [19] Long-Term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis
    Samur, Sumeyye
    Klebanoff, Matthew
    Banken, Reiner
    Pratt, Daniel S.
    Chapman, Rick
    Ollendorf, Daniel A.
    Loos, Anne M.
    Corey, Kathleen
    Hur, Chin
    Chhatwal, Jagpreet
    HEPATOLOGY, 2017, 65 (03) : 920 - 928
  • [20] Long-term Clinical Outcomes and Cost-Effectiveness of Obeticholic Acid for Treatment of Primary Biliary Cholangitis
    Samur, Sumeyye
    Hur, Chin
    Klebanoff, Matthew
    Pratt, Daniel S.
    Banken, Reiner
    Chapman, Richard H.
    Ollendorf, Daniel A.
    Chhatwal, Jagpreet
    HEPATOLOGY, 2016, 64 : 54A - 54A
12345